Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth

Laiba Immad

Wed, February 18, 2026 at 3:11 PM GMT+9 2 min read

In this article:

TFC

+0.58%

CYTK

+0.54%

Cytokinetics, Incorporated (NASDAQ:CYTK) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.

Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth

Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the fifteen best healthcare stocks on our list.

TheFly reported on February 3 that Truist raised its price target on CYTK to $92 from $84 and maintained a Buy rating. The company revised its model ahead of its Q4 results to account for the impact of the drug’s free supply program, the annual WAC price of $108,400 for Myqorzo, and increased operational costs anticipated in 2026 to support short-term operations. Truist’s updated prognosis, which takes these considerations into account, is reflected in the adjustment.

Cytokinetics, Incorporated (NASDAQ:CYTK) reported on January 27 that MYQORZO (aficamten) is now available in the United States in tablet form in dosages of 5 mg, 10 mg, 15 mg, and 20 mg. The medication is for treating obstructive hypertrophic cardiomyopathy (oHCM) symptoms and functional capacity in adults. According to President and CEO Robert I. Blum, the launch signifies the company’s entry into the commercial biopharmaceutical stage and demonstrates its dedication to patients with oHCM.

The introduction of MYQORZO is supported by the fully operational REMS program, which is a specialty pharmacy distribution network, and years of clinical development and commercial readiness that ensure patients have access to this new treatment while benefiting from the company’s focus on patient safety and the broader HCM community.

Cytokinetics, Incorporated (NASDAQ:CYTK) is a U.S. biopharmaceutical innovator focused on muscle biology, developing first‑in‑class muscle activators and inhibitors that target sarcomere function to treat debilitating cardiovascular and neuromuscular diseases, advancing novel therapies grounded in deep science and rigorous research.

While we acknowledge the potential of CYTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.

Terms and Privacy Policy

Privacy Dashboard

More Info